Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Cancer survival rates
The most common type of cancer among children and adolescents is leukemia, followed by brain and other central nervous system tumors. Survival rates for most childhood cancers have improved, with a notable improvement in acute lymphoblastic lymphoma (the most common childhood cancer). Due to improved treatment, the 5-year survival rate for acute lymphoblastic lymphoma has increased from less than 10% in the 1960s to about 90% during the time period 2003-2009.